Clinical trial
A Large, Prospective, Randomized, Multicenter Clinical Study Evaluating the Safety and Efficacy of the Post-marketing Drug-eluting Stent System (Rapamycin) - the EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT
NCT03716011 is registered in ClinicalTrials.gov with JW Medical Systems Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Large, Prospective, Randomized, Multicenter Clinical Study Evaluating the Safety and Efficacy of the Post-marketing Drug-eluting Stent System (Rapamycin) - the EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT
- Lead sponsor
- JW Medical Systems Ltd
- Phase
- Not applicable
- Overall status
- Unknown status
- Start date
- December 20, 2018
- Completion date
- December 20, 2025
- Enrollment
- 2,700 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.